High-dose therapy and autologous bone marrow transplantation in first complete remission for adult patients with high-grade non-Hodgkin's lymphoma: the EBMT experience. Lymphoma Working Party of the European Group for Bone Marrow Transplantation

One hundred and eighteen patients presenting with high-grade non-Hodgkin's lymphoma, undergoing autologous bone marrow transplantation (ABMT) in first complete remission (CR), have been reported to the European Group for Bone Marrow Transplantation (EBMT). Of these, 102 were eligible for inclus...

Full description

Saved in:
Bibliographic Details
Published in:Annals of oncology 1994, Vol.5 Suppl 2, p.155
Main Authors: Sweetenham, J W, Proctor, S J, Blaise, D, De Laurenzi, A, Pearce, R, Taghipour, G, Goldstone, A H, Laurenzi A [corrected to De Laurenzi, A ]
Format: Article
Language:English
Subjects:
Adolescent
Adult
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Bleomycin - administration & dosage
Bone Marrow Purging
Bone Marrow Transplantation
Combined Modality Therapy
Cyclophosphamide - administration & dosage
Dexamethasone - administration & dosage
Doxorubicin - administration & dosage
Female
Humans
Leucovorin - administration & dosage
Life Tables
Lymphoma, Non-Hodgkin - classification
Lymphoma, Non-Hodgkin - drug therapy
Lymphoma, Non-Hodgkin - mortality
Lymphoma, Non-Hodgkin - pathology
Lymphoma, Non-Hodgkin - therapy
Male
Methotrexate - administration & dosage
Middle Aged
Prednisone - administration & dosage
Remission Induction
Risk Factors
Survival Analysis
Treatment Outcome
Vincristine - administration & dosage
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:One hundred and eighteen patients presenting with high-grade non-Hodgkin's lymphoma, undergoing autologous bone marrow transplantation (ABMT) in first complete remission (CR), have been reported to the European Group for Bone Marrow Transplantation (EBMT). Of these, 102 were eligible for inclusion in this study following review of registration forms. Patients with lymphoblastic lymphoma were excluded. Remission induction and high-dose regimens varied between contributing centres. A maintained CR was observed in 90% of patients. Early relapse was observed in 6%, and 4% suffered toxic deaths. With a median follow-up of 45 months (3-112 months), the 5-year actuarial overall and progression-free survivals are both 70%. Nineteen (18%) patients relapsed at a median of 3.5 months (0.25-52 months) after ABMT, only 1 achieving a further durable CR. The only factor with prognostic significance was histological subtype, with diffuse small noncleaved-cell lymphoma having a significantly worse outcome. High-dose therapy and ABMT has produced effective consolidation of first remission in this group of patients, even in those with poor prognostic features at presentation.
ISSN:0923-7534